Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on May 10, 2019 12:34pm
202 Views
Post# 29734746

RE:RE:Pending results

RE:RE:Pending resultsGreat the Drug is GI safe at this dosage, now proven!
The drug is an NSAID made to reduce pain. If it is GI safe but doesn't reduce pain to an acceptable level then it is useless. 
So to recap we KNOW its GI safe.
What we don't know is how effective it is at these dosages (150mg, 200mg, 250mg). That's why this study is critical. If it doesn't reduce pain to an acceptable level then might as well throw it away.

Now to derisk this, the previous small study on 10 or 12 people was not a double blind study but did achieve pretty high womac scores. there was no control (no placebo) to compare so you can't prove if its truly effective plus study size was too small so no scientific significance to the study. However the results were positive. Another way to derisk it is now that hundreds of people were given this drug with no significant side effects at this dosage it is looking favorable to be safe and well tolerated while reducing risk of a major side effect being uncovered. Lastly the blood sample collected at these dosage shows naproxen like structures indicating that this dosage might have a similar effectiveness of naproxen (this is my interpretations, don't quote me on this) but showing similar cox inhibition as naproxen which bodes well for chances of it working. 

In the end the results from this study is critical. Until proven, majors will not invest in it. 

Bullboard Posts